His programme aims to take potential biomarkers, validate them robustly, and then incorporate them into frameworks that allows them to influence clinical management in ways that can be proven to improve outcomes. In addition to leveraging the in-house biomarker and diagnostics expertise present at Imperial College he has led the formation of the Predicting Outcomes in Esophageal Malignancy (POEM) Biomarkers consortium which is composed of centres across the UK and Europe (St Marys, UCL, Belfast, Dublin and Rotterdam at present). This group are all working towards the development of clinically applicable biomarkers for use at multiple points in the patient's pathway.